Ensem Therapeutics Inc. has gained IND clearance from the FDA for ETX-636, a novel allosteric pan-mutant-selective PI3Kα inhibitor and degrader. A first-in-human trial will begin this quarter. The ...

It is designed to block the signalling pathway of the RAS-phosphatidylinositol 3-kinase alpha (PI3Kα), which plays an important role in the development and progression of solid tumours.

The company calls the candidate the "first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα." There was also a 33% objective response rate across all patients ...

Morningstar brands and products Company Portfolio ...

Ensem Therapeutics announces U.S. FDA IND clearance to start ETX-636 clinical trials. Also, ENSEM will present preclinical ...

The highlights included a potent KRAS inhibitor with impressive tumor growth inhibition in mouse models, a novel PI3Kα inhibitor demonstrating efficacy against key mutations, and a selective ...

"We are thrilled to present the first clinical data for our lead program, OKI-219, which is the only highly selective PI3Kα H1047R inhibitor molecule in the clinic,” said Nicholas Saccomano, Ph.D., ...

VVD-159642, Vividion’s fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Kα, a key signaling ...

First-in-human trial of ETX–636 to begin in Q2 2025 in patients with tumors harboring an activating PI3Kα mutation, including breast cancer - ETX-636 preclinical data to be presented at the ...

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target ...